12 Month Price Forecast For PACB
Distance to PACB Price Forecasts
PACB Price Momentum
🤔 Considering PacBio (PACB)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 11:55 AM UTC
PACB Analyst Ratings & Price Targets
Based on our analysis of 18 Wall Street analysts, PACB has a consensus that is neutral. The median price target is $2.75, with forecasts ranging from $2.00 to $6.00. Currently, there are 7 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
With PACB currently trading at $1.81, the median price forecast suggests a 51.9% upside. The most optimistic forecast comes from Sung Ji Nam at Scotiabank, projecting a 231.5% upside, while John Sourbeer at UBS provides the most conservative target, suggesting a 10.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PACB Analyst Consensus
PACB Price Target Range
Latest PACB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PACB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 11, 2024 | Piper Sandler | David Westenberg | Neutral | Maintains | $2.50 |
| Nov 11, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $6.00 |
| Nov 11, 2024 | UBS | John Sourbeer | Neutral | Downgrade | $2.00 |
| Aug 28, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $7.00 |
| Aug 13, 2024 | Stephens & Co. | Overweight | Maintains | $0.00 | |
| Aug 12, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $2.00 |
| Aug 8, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $3.50 |
| Aug 8, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $3.00 |
| Jun 3, 2024 | Jefferies | Tycho Peterson | Buy | Initiates | $4.00 |
| May 15, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $4.00 |
| May 13, 2024 | Piper Sandler | David Westenberg | Neutral | Maintains | $2.00 |
| May 10, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $2.00 |
| Apr 22, 2024 | JP Morgan | Rachel Vatnsdal | Neutral | Downgrade | $0.00 |
| Apr 19, 2024 | Goldman Sachs | Matthew Sykes | Neutral | Maintains | $2.50 |
| Apr 18, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $8.00 |
| Apr 18, 2024 | Bernstein | Eve Burstein | Outperform | Maintains | $2.50 |
| Apr 18, 2024 | Goldman Sachs | Matthew Sykes | Neutral | Downgrade | $2.50 |
| Apr 17, 2024 | TD Cowen | Daniel Brennan | Buy | Maintains | $2.50 |
| Apr 10, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $3.00 |
| Apr 10, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $7.00 |
Stocks Similar to Pacific Biosciences of California Inc
The following stocks are similar to PacBio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pacific Biosciences of California Inc (PACB) Financial Data
Pacific Biosciences of California Inc has a market capitalization of $500.34M with a P/E ratio of -1.5x. The company generates $173.15M in trailing twelve-month revenue with a -227.7% profit margin.
Revenue growth is -28.2% quarter-over-quarter, while maintaining an operating margin of -140.1% and return on equity of -64.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Pacific Biosciences of California Inc (PACB) Company Overview
About Pacific Biosciences of California Inc
Provides advanced sequencing solutions for genetic analysis.
The company generates revenue by designing, developing, and manufacturing sequencing systems and consumable products that facilitate genetic analysis. Its offerings include single molecule real-time (SMRT) technology, various reagent kits, and specialized sequencing systems, which are sold to a diverse customer base including academic institutions, laboratories, and pharmaceutical companies.
Pacific Biosciences has established collaborations with notable organizations, enhancing its research capabilities and market reach. It operates globally through a robust sales force and distribution partners, ensuring its products are accessible in multiple regions. The company has a history of innovation since its incorporation in 2000 and was previously known as Nanofluidics, Inc.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
796
CEO
Mr. Christian O. Henry M.B.A.
Country
United States
IPO Year
2010
Website
www.pacb.comPacific Biosciences of California Inc (PACB) Latest News & Analysis
PacBio's preliminary Q4 2024 results are poor due to decreased instrument sales, but new product launches and a clinical focus may drive growth in 2025.
Dismal fourth-quarter results may signal short-term challenges for PacBio, but upcoming product launches and a strategic clinical focus could drive future growth, impacting stock performance.
The company has started shipping the Vega™ benchtop system earlier than expected, expanding access to HiFi sequencing for additional customers.
Early shipment of the Vega™ system indicates strong demand and operational efficiency, potentially boosting revenue and market share for the company, positively impacting stock performance.
PacBio (NASDAQ: PACB) reported a study by Radboud University highlighting its HiFi long-read sequencing technology's effectiveness in diagnosing rare diseases, potentially streamlining testing processes.
PacBio's technology could streamline genetic testing, reducing costs and time for diagnosing rare diseases, enhancing its market position and growth potential, which is attractive to investors.
PacBio reports positive study results for its HiFi long-read sequencing technology, demonstrating effectiveness in identifying genetic causes of rare diseases.
Positive results for PacBio's HiFi sequencing can drive demand for its technology, potentially increasing revenue and market share in the genomic testing sector, impacting stock performance.
PACB and Intus Bio have partnered to launch GutID, the first commercial test for human gut health.
The launch of GutID by PACB and Intus Bio signifies innovation in gut health diagnostics, potentially expanding market opportunities and driving revenue growth for both companies.
PacBio and Intus Bio launched GutID, the first commercial human gut health test using advanced sequencing and AI, offering comprehensive accuracy in gut microbiome testing.
The launch of GutID by PacBio and Intus Bio could drive significant revenue growth and market share in the burgeoning gut health sector, impacting stock performance and investor sentiment.
Frequently Asked Questions About PACB Stock
What is Pacific Biosciences of California Inc's (PACB) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Pacific Biosciences of California Inc (PACB) has a median price target of $2.75. The highest price target is $6.00 and the lowest is $2.00.
Is PACB stock a good investment in 2025?
According to current analyst ratings, PACB has 7 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for PACB stock?
Wall Street analysts predict PACB stock could reach $2.75 in the next 12 months. This represents a 51.9% increase from the current price of $1.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pacific Biosciences of California Inc's business model?
The company generates revenue by designing, developing, and manufacturing sequencing systems and consumable products that facilitate genetic analysis. Its offerings include single molecule real-time (SMRT) technology, various reagent kits, and specialized sequencing systems, which are sold to a diverse customer base including academic institutions, laboratories, and pharmaceutical companies.
What is the highest forecasted price for PACB Pacific Biosciences of California Inc?
The highest price target for PACB is $6.00 from Sung Ji Nam at Scotiabank, which represents a 231.5% increase from the current price of $1.81.
What is the lowest forecasted price for PACB Pacific Biosciences of California Inc?
The lowest price target for PACB is $2.00 from John Sourbeer at UBS, which represents a 10.5% increase from the current price of $1.81.
What is the overall PACB consensus from analysts for Pacific Biosciences of California Inc?
The overall analyst consensus for PACB is neutral. Out of 18 Wall Street analysts, 7 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $2.75.
How accurate are PACB stock price projections?
Stock price projections, including those for Pacific Biosciences of California Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
